The study brings much hope to patients with brain and spinal cord cancers.
A small pilot trial involving patients with lymphoma of the brain and/or spinal cord has shown that CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) can be a viable treatment option for patients who often have little hope, according to a press release by Dana-Farber Cancer Institute investigators published on Sunday. “For many patients with lymphoma of the central nervous system, there aren’t great treatment options,” said Dana-Farber’s Caron Jacobson, MD, MMSc, who led the trial.
Our early results suggest that expanding the applicability of CAR-T cells to this indication could improve patient outcomes.
Mohammed Haneefa Nizamudeen/iStock.
Lymphomas typically feature aggressive tumors that can spread to the brain and spinal cord after they originate in other parts of the body. These cancers are often difficult to treat and patients do not survive more than two years.
Comments are closed.